Amylyx Pharmaceuticals Ownership | Who Owns Amylyx Pharmaceuticals?


Amylyx Pharmaceuticals Ownership Summary


Amylyx Pharmaceuticals is owned by 73.12% institutional investors, 11.41% insiders, and 15.48% retail investors. Perceptive advisors is the largest institutional shareholder, holding 9.95% of AMLX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.16% of its assets in Amylyx Pharmaceuticals shares.

AMLX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAmylyx Pharmaceuticals73.12%11.41%15.48%
SectorHealthcare Stocks 56.95%9.28%33.77%
IndustryBiotech Stocks 68.60%8.91%22.49%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Perceptive advisors6.77M9.95%$25.61M
Tcg crossover management4.64M6.82%$17.55M
Vanguard group2.69M3.95%$10.18M
Blackrock2.67M3.93%$5.07M
Blackrock funding, inc. /de2.28M3.35%$8.61M
Almitas capital2.03M2.98%$7.68M
683 capital management1.93M2.83%$7.30M
Goldman sachs group1.86M2.73%$7.03M
Abrdn1.72M2.53%$6.51M
Nantahala capital management1.45M2.13%$5.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tcg crossover management4.64M1.72%$17.55M
Almitas capital2.03M1.68%$7.68M
Saturn v capital management889.07K1.32%$3.36M
Aldebaran capital262.75K0.94%$993.21K
Perceptive advisors6.77M0.71%$25.61M
683 capital management1.93M0.45%$7.30M
Alpha wave global, lp148.63K0.26%$561.81K
Nantahala capital management1.45M0.24%$5.49M
Ikarian capital201.19K0.10%$760.49K
Point72 asia (singapore) pte.72.86K0.07%$275.42K

Top Buyers

HolderShares% AssetsChange
Perceptive advisors6.77M0.71%4.65M
Saturn v capital management889.07K1.32%889.07K
Qube research780.57K0.00%596.67K
Jacobs levy equity management589.11K0.00%589.11K
Fmr731.36K0.00%510.36K

Top Sellers

HolderShares% AssetsChange
Franklin resources---1.86M
Blackrock2.67M0.00%-1.80M
Boxer capital---1.50M
Alyeska investment group823.42K0.01%-1.20M
Acadian asset management611.93K0.01%-1.16M

New Positions

HolderShares% AssetsChangeValue
Saturn v capital management889.07K1.32%889.07K$3.36M
Jacobs levy equity management589.11K0.00%589.11K$1.12M
Orbimed advisors348.00K0.03%348.00K$1.32M
Wellington management group llp209.71K0.00%209.71K$792.70K
Exoduspoint capital management, lp106.24K0.00%106.24K$402.00K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-10.00
Kelly financial services-33.00
Gamma investing-35.00
Point72 asset management-200.00
Fernwood investment management-200.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202413012.07%49,788,21014.69%731.80%6518.18%4014.29%
Sep 30, 2024116-8.66%43,410,314-0.50%631.54%56-3.45%35-25.53%
Jun 30, 2024127-28.25%43,627,452-12.05%641.19%58-33.33%47-2.08%
Mar 31, 2024177-14.08%49,605,091-17.71%730.92%87-25.64%48-4.00%
Dec 31, 20232068.99%60,281,7332.30%891.16%11710.38%502.04%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.48M2.16%-
abrdn Healthcare Investors1.20M1.74%-17.82K
Vanguard Institutional Extnd Mkt Idx Tr727.34K1.06%-
Vanguard Small Cap Index646.02K0.95%1.52K
Fidelity Select Biotechnology782.81K0.91%-
abrdn Life Sciences Investors527.22K0.77%-7.85K
Jupiter Merian Glb Eq AbsRet I USD Acc480.21K0.71%185.87K
Vanguard Small Cap Growth Index Inv357.96K0.53%-1.58K
Schwab Small-Cap Equity331.23K0.49%240.56K
iShares Biotechnology ETF342.44K0.40%67.53K

Recent Insider Transactions


DateNameRoleActivityValue
Feb 03, 2025Mazzariello Gina Chief Legal OfficerSell$12.84K
Feb 03, 2025Cohen Joshua B Co-Chief Executive OfficerSell$41.11K
Feb 03, 2025Klee Justin B. Co-Chief Executive OfficerSell$41.10K
Jan 06, 2025Klee Justin B. Co-Chief Executive OfficerSell$30.20K
Jan 06, 2025Cohen Joshua B Co-Chief Executive OfficerSell$30.23K

Insider Transactions Trends


DateBuySell
2025 Q1-5
2024 Q4-1
2024 Q334
2024 Q221
2024 Q1-9

AMLX Ownership FAQ


Who Owns Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals shareholders are primarily institutional investors at 73.12%, followed by 11.41% insiders and 15.47% retail investors. The average institutional ownership in Amylyx Pharmaceuticals's industry, Biotech Stocks , is 68.60%, which Amylyx Pharmaceuticals exceeds.

Who owns the most shares of Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals’s largest shareholders are Perceptive advisors (6.77M shares, 9.95%), Tcg crossover management (4.64M shares, 6.82%), and Vanguard group (2.69M shares, 3.95%). Together, they hold 20.72% of Amylyx Pharmaceuticals’s total shares outstanding.

Does Blackrock own Amylyx Pharmaceuticals?

Yes, BlackRock owns 3.93% of Amylyx Pharmaceuticals, totaling 2.67M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.07M$. In the last quarter, BlackRock decreased its holdings by -1.805M shares, a -40.34% change.

Who is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tcg crossover management is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 1.72% of its assets in 4.64M Amylyx Pharmaceuticals shares, valued at 17.55M$.

Who is the top mutual fund holder of Amylyx Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Amylyx Pharmaceuticals shares, with 2.16% of its total shares outstanding invested in 1.48M Amylyx Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools